Literature DB >> 22060732

Prostate cancer survival in Trinidad: Is PSA a prognostic factor?

Kameel Mungrue1, Suresh Moonan, Maryam Mohammed, Saara Hyatali.   

Abstract

BACKGROUND: Prostate cancer is the most common malignancy among men in the western hemisphere, including Trinidad and Tobago. The aim of this study is to describe the epidemiological features of prostate cancer among patients admitted to a tertiary level teaching hospital during 2002 to 2005. We assessed the long-term survival of patients with prostate cancer and the epidemiology of the disease.
METHODS: We reviewed the admissions data for the period 2002-2005. Demographic, clinical and outcomes (survival or death) data were collected and analysed, using SPSS version 16. Statistical analysis included Kaplan-Mier survival analysis, Cox regression models and the log-rank test. A p value of <0.05 was considered statistically significant.
RESULTS: Of the 1250 cases reviewed, 242 participants were selected. Patients of African ancestry, older than 60 years and a Gleason score greater than 7 had an increased risk of mortality. Patients with prostate-specific antigen (PSA) ≥100 ng/L had a 3-fold increased risk of mortality. Survival rates declined between 2002 and 2005.
CONCLUSION: This is the first study of its kind to demonstrate survival rates among patients with prostate cancer in Trinidad. The following epidemiological features were identified: average age of occurrence of 71 years, ethnic disparity with higher occurrence in African men than all other ethnic groups and a PSA of >100 ng/dL. These features were associated with a 3-fold higher risk of death. A Gleason score of 8 to 10 was also associated with lower survival rates.

Entities:  

Year:  2011        PMID: 22060732      PMCID: PMC3529730          DOI: 10.5489/cuaj.11006

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  22 in total

Review 1.  Impact of screening on incidence and mortality of prostate cancer in the United States.

Authors:  A L Potosky; E J Feuer; D L Levin
Journal:  Epidemiol Rev       Date:  2001       Impact factor: 6.222

2.  Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma.

Authors:  Klaus Brasso; Ib Jarle Christensen; Julia S Johansen; Børge Teisner; Patrick Garnero; Paul A Price; Peter Iversen
Journal:  Prostate       Date:  2006-04-01       Impact factor: 4.104

3.  Cancer incidence and mortality in Europe, 2004.

Authors:  P Boyle; J Ferlay
Journal:  Ann Oncol       Date:  2005-02-17       Impact factor: 32.976

4.  Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis.

Authors:  R K Nam; N Fleshner; E Rakovitch; L Klotz; J Trachtenberg; R Choo; G Morton; C Danjoux
Journal:  J Urol       Date:  1999-05       Impact factor: 7.450

Review 5.  Impact of screening on prostate cancer rates and trends.

Authors:  C Mettlin
Journal:  Microsc Res Tech       Date:  2000-12-01       Impact factor: 2.769

6.  A 6-year analysis of the clinicopathological profile of patients with prostate cancer at the University Hospital of the West Indies, Jamaica.

Authors:  Kathleen C M Coard; Desiree H-A Skeete
Journal:  BJU Int       Date:  2008-12-08       Impact factor: 5.588

7.  Screening and prostate-cancer mortality in a randomized European study.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Antonio Berenguer; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Bert G Blijenberg; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

8.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

9.  Short- and long-term mortality with localized prostate cancer.

Authors:  Arnaud Merglen; Franz Schmidlin; Gerald Fioretta; Helena M Verkooijen; Elisabetta Rapiti; Roberto Zanetti; Raymond Miralbell; Christine Bouchardy
Journal:  Arch Intern Med       Date:  2007-10-08

10.  Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Authors:  Scott M Lippman; Eric A Klein; Phyllis J Goodman; M Scott Lucia; Ian M Thompson; Leslie G Ford; Howard L Parnes; Lori M Minasian; J Michael Gaziano; Jo Ann Hartline; J Kellogg Parsons; James D Bearden; E David Crawford; Gary E Goodman; Jaime Claudio; Eric Winquist; Elise D Cook; Daniel D Karp; Philip Walther; Michael M Lieber; Alan R Kristal; Amy K Darke; Kathryn B Arnold; Patricia A Ganz; Regina M Santella; Demetrius Albanes; Philip R Taylor; Jeffrey L Probstfield; T J Jagpal; John J Crowley; Frank L Meyskens; Laurence H Baker; Charles A Coltman
Journal:  JAMA       Date:  2008-12-09       Impact factor: 56.272

View more
  5 in total

1.  Herbal remedies and functional foods used by cancer patients attending specialty oncology clinics in Trinidad.

Authors:  Yuri N Clement; Varune Mahase; Annelise Jagroop; Kelly Kissoon; Aarti Maharaj; Prashant Mathura; Chrys Mc Quan; Divya Ramadhin; Cherrista Mohammed
Journal:  BMC Complement Altern Med       Date:  2016-10-21       Impact factor: 3.659

2.  A Clinicopathological Profile of Prostate Cancer in Trinidad and Tobago.

Authors:  Ian Hosein; Rajendra Sukhraj; Lester Goetz; Nastassia Rambarran; Satyendra Persaud
Journal:  Adv Urol       Date:  2016-07-17

3.  Beliefs that contribute to delays in diagnosis of prostate cancer among Afro-Caribbean men in Trinidad and Tobago.

Authors:  Michelle King-Okoye; Anne Arber; Sara Faithfull
Journal:  Psychooncology       Date:  2019-04-29       Impact factor: 3.894

Review 4.  The current state of prostate cancer treatment in Trinidad and Tobago.

Authors:  Satyendra Persaud; Maliza Persaud; Lester Goetz; Dylan Narinesingh
Journal:  Ecancermedicalscience       Date:  2018-04-24

5.  Prostate-specific antigen-based screening in Afro-Caribbean men: a survey of members of the Caribbean Urological Association.

Authors:  Satyendra Persaud; William D Aiken
Journal:  Ecancermedicalscience       Date:  2018-06-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.